Heplatinum Pharmaceutical Holdings Co., Ltd. is an investment holding company mainly engaged in the development of innovative therapies in the field of tumor immunology and immune diseases. The company's products include bartolizumab, mainly for immune thrombocytopenia, thyroid associated ophthalmopathy, myasthenia gravis, optic neuromyelitis spectrum diseases, and tenacil, mainly for dry eye diseases. In addition, the company also studies and develops tumor immunization product lines, including internally developed new-generation tumor immune assets for the treatment of immune desert, immune rejection and inflammatory tumors.
CEO： Jingsong Wang
Market： Hong Kong motherboard